Formation and Investigation of Cell‐Derived Nanovesicles as Potential Therapeutics against Chronic Liver Disease

Abstract

This study aims to offer a new therapeutic approach using cell‐derived nanovesicles (cdNVs) to overcome the lack of effective treatments for liver fibrosis, a reversible chronic liver disease. To achieve this goal we established the formation and purification of cdNVs from untreated, quiescent‐like, or activated LX‐2 cells, an immortalized human hepatic stellate cell (HSC) line with key features of transdifferentiated HSCs. Analysis of the genotype and phenotype of naïve and transdifferentiated LX‐2 cells activated through transforming growth factor beta 1 (TGF‐β1), following treatment with cdNVs, revealed a concentration‐dependent fibrosis regression. The beneficial fibrosis‐resolving effects of cdNVs are linked to their biomolecular corona. Liposomes generated using lipids extracted from cdNVs exhibit a reduced anti‐fibrotic response in perpetuated LX‐2 cells and show a reduced cellular uptake. However, incubation with soluble factors collected during purification results in a new corona, thereby restoring fibrosis regression activity. Overall, cdNVs display encouraging therapeutic properties, making them a promising candidate for the development of liver fibrosis resolving therapeutics.This article is protected by copyright. All rights reserved

3D‐Printed Lipid Mesophases for the Treatment of Chronic Liver Disease

“…Post-treatment, TRIzol reagent (Thermofischer, USA) was used to isolate total RNA per instructions. [64] Briefly, cells lysed with TRIzol in the plate were transferred to Axygen tubes (Corning, USA). Chloroform (1/5 TRIzol volume) was added, followed by vortexing and 20 min centrifugation (4 °C, 16 000 g; Hermle Z 366 K centrifuge, Faust, Switzerland).…”